

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
CIN: L24230GJ1993PLC019050



February 11, 2021

National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Sub: Conclusion of settlement proceedings with SEBI

Dear Sir / Madam,

We wish to inform the stock exchanges that the Securities and Exchange Board of India (SEBI) has today issued Settlement Order(s), dated February 11, 2021 (source: <https://www.sebi.gov.in/>), in respect of adjudication proceedings initiated pursuant to the show cause notices issued by SEBI on May 19, 2020 to Sun Pharmaceutical Industries Limited, and the Whole-time Directors and certain officers at the relevant time.

The said show cause notices pertained to alleged violations of certain provisions of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, relevant for compliances pertaining to related parties, and were issued pursuant to investigation conducted after receipt of two whistle blower complaints by SEBI.

The aforementioned proceedings have been settled and disposed as per the settlement terms set out in the Settlement Order(s), without admitting or denying the findings of fact and conclusions of law in accordance with the terms of SEBI (Settlement of Administrative and Civil Proceedings) Regulations 2018, in order to expeditiously close the matter. The aggregate settlement charges were Rs.2,92,10,250 (Two crores, ninety two lakhs, ten thousand, two hundred and fifty).

This is for your information and dissemination.

Thanking you,

Yours faithfully,

For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta
Compliance Officer